Fulgent Genetics (FLGT) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held on May 14, 2026, to elect four directors, ratify the appointment of Deloitte & Touche LLP as auditor, approve executive compensation, and adopt the 2026 Equity Incentive Plan.

• Shareholders of record as of March 20, 2026, are eligible to vote, with voting available online, by phone, mail, or in person.

• The company emphasizes sustainability, cybersecurity, and diversity in governance, and continues to focus on growth in diagnostics and pharma pipelines.

Voting matters and shareholder proposals

• Four directors are nominated for one-year terms: Ming Hsieh, Linda Dong, Michael Nohaile, Ph.D., and Regina Groves.

• Ratification of Deloitte & Touche LLP as independent auditor for 2026 is proposed.

• Advisory approval of executive compensation (Say-on-Pay) is sought.

• Approval of the 2026 Equity Incentive Plan, reserving 2,000,000 new shares, is proposed.

• Shareholder proposals and director nominations for 2027 must be submitted by December 3, 2026.

Board of directors and corporate governance

• The board consists of four nominees, with three independent directors.

• Committees include Audit, Compensation, and Nominating & Governance, all composed of independent directors.

• The board encourages diversity, limits on outside directorships, and regular performance evaluations.

• Board leadership combines CEO and Chair roles, with risk oversight delegated to committees.